We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+75.99%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.76B
AUM Growth
+$607M
Cap. Flow
+$235M
Cap. Flow %
13.41%
Top 10 Hldgs %
43.13%
Holding
124
New
28
Increased
25
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$34.5M
2
CYTK icon
Cytokinetics
CYTK
+$28M
3
VTYX
Ventyx Biosciences
VTYX
+$19.1M
4
ROIV icon
Roivant Sciences
ROIV
+$17.8M
5
FBRX icon
Forte Biosciences
FBRX
+$17.3M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$66.7M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$56.3M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$42.8M
4
MRUS
Merus
MRUS
+$26.9M
5
SLNO
Soleno Therapeutics
SLNO
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.68%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSP icon
101
Inspire Medical Systems
INSP
$1.53B
– –
-50,000
Closed -$3.71M
JAZZ icon
102
Jazz Pharmaceuticals
JAZZ
$15.3B
– –
-25,000
Closed -$3.29M
KPTI icon
103
CALL
Karyopharm Therapeutics
KPTI
$169M
– –
-157,600
Closed -$1.03M
MIST icon
104
Milestone Pharmaceuticals
MIST
$147M
– –
-666,666
Closed -$1.33M
MNPR icon
105
Monopar Therapeutics
MNPR
$709M
– –
-79,483
Closed -$6.49M
MRUS
106
DELISTED
Merus
MRUS
– –
-285,769
Closed -$26.9M
NTLA icon
107
CALL
Intellia Therapeutics
NTLA
$1.53B
– –
-300,000
Closed -$5.18M
OCUL icon
108
Ocular Therapeutix
OCUL
$1.91B
– –
-239,000
Closed -$2.79M
OLMA icon
109
CALL
Olema Pharmaceuticals
OLMA
$991M
– –
-250,000
Closed -$2.45M
OLMA icon
110
Olema Pharmaceuticals
OLMA
$991M
– –
-250,000
Closed -$2.45M
OMER icon
111
PUT
Omeros
OMER
$697M
– –
-1,133,900
Closed -$4.65M
PCVX icon
112
Vaxcyte
PCVX
$8.01B
– –
-125,000
Closed -$4.5M
RPTX
113
DELISTED
Repare Therapeutics
RPTX
– –
-200,000
Closed -$352K
SLNO
114
DELISTED
Soleno Therapeutics
SLNO
– –
-200,000
Closed -$13.5M
SPRY icon
115
ARS Pharmaceuticals
SPRY
$640M
– –
-2,500
Closed -$25.1K
SPY icon
116
State Street SPDR S&P 500 ETF Trust
SPY
$781B
– –
-84,490
Closed -$56.3M
TARS icon
117
Tarsus Pharmaceuticals
TARS
$2.45B
– –
-125,000
Closed -$7.43M
UTHR icon
118
United Therapeutics
UTHR
$22.5B
– –
-5,000
Closed -$2.1M
VRNA
119
DELISTED
Verona Pharma
VRNA
– –
-625,000
Closed -$66.7M
ATYR
120
PUT
aTyr Pharma
ATYR
$47.7M
– –
-2,100,000
Closed -$1.51M
1 2 3 4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Affinity Asset Advisors held 124 positions worth $1.76B, up 53% from $1.15B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $235M of net new capital in Q4 2025, opening 28 new positions and adding to 25 existing holdings. Its largest new stake was Praxis Precision Medicines: 185,000 shares worth $54.5M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $42.8M trimmed.

  • Affinity Asset Advisors's largest Q4 2025 buy was Praxis Precision Medicines: 185,000 shares worth $54.5M.
  • Affinity Asset Advisors added most to Cytokinetics in Q4 2025, an estimated $28M increase.
  • Affinity Asset Advisors's biggest Q4 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $42.8M.
  • Affinity Asset Advisors fully exited Verona Pharma in Q4 2025, selling an estimated $66.7M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $1.76B portfolio in Q4 2025.
  • Affinity Asset Advisors opened 28 new positions and closed 29 in Q4 2025.
  • Affinity Asset Advisors's portfolio value rose 53% quarter-over-quarter to $1.76B.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.